The latest evidence on the efficacy and safety of messenger RNA (mRNA) vaccines for glioblastoma (GBM) is promising but still primarily in the preclinical and early clinical trial stages.
In summary, mRNA vaccines for glioblastoma show promising efficacy in preclinical models and early clinical trials, with a favorable safety profile. Continued research and clinical trials are necessary to fully establish their therapeutic potential and optimize their use in clinical practice.